Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS OIG To Investigate Drug Shortages, Rebates, Other Pharma Issues In 2013

Executive Summary

A number of topical issues will be investigated by the HHS Office of Inspector General, according to its work plan for fiscal year 2013. Pharma industry issues are concentrated in the Medicare and Medicaid space.

You may also be interested in...

HHS Inspector General Investigating Drug Savings For Medicare In FY 2014 Work Plan

OIG is examining how Medicare could benefit if it shared in the drug discounts available through the 340B program, the potential impact of changes to Part B ASP reporting and other Medicare and Medicaid drug-related topics during this and the coming fiscal year.

Reimbursement News, In Brief

Sen. Wyden questions Xeljanz pricing at Senate hearing and Sen. Nelson wants new OIG review of Medicaid versus Medicare drug rebates. GAO compares VA, DoD drug purchasing in report.

Medicare Part D Plans Expanding Five-Tier Formularies, Preferred Networks In 2013

A review of Part D plan design trends among the leading sponsors shows that Humana has switched to five-tier formularies, UnitedHealth is using a preferred pharmacy network and CVS Caremark is sponsoring plans that include community-based independents in its preferred network.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts